SAR-442720 is under clinical development by Sanofi and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAR-442720’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAR-442720 (RMC-4630) is under development for the treatment of relapsed/refractory solid tumors including advanced colorectal cancer, non small cell lung cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, neuroendocrine/carcinoid cancer, gastroesophageal junction carcinoma, gallbladder/biliary cancer, lip cancer, oral cavity and pharynx, esophageal cancer, stomach cancer, small intestine cancer, colon cancer, rectal cancer, anal cancer, liver cancer, other digestive organ, laryngeal cancer, bones and joints, soft tissue sarcoma, mycosis fungoides, cervical cancer, corpus uteri, ovarian cancer, prostate cancer, urinary bladder cancer, kidney cancer, brain cancer and nervous system, thyroid cancer, unknown sites, other endocrine system, Kaposi sarcoma, melanoma and skin cancer. It is administered through oral route. The drug candidate acts by targeting SHP2. It is developed based on breakthrough modular synthesis technology.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of SAR-442720’s drug-specific PTSR and LoA scores, buy the report here.